Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
2024-518061-10-00Phase 2Authorised
- Sponsor
- CHU Brugmann
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin in alcohol use disorder (AUD), sponsored by CHU Brugmann. Primary endpoints: Primary clinical outcome: change in percentage of heavy drinking days, Feasibility outcome: recruitment and retention and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2024-518061-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518061-10-00.